Hobart Rogers

The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using <i>In Vitro</i> Data in Lieu of a Clinical Trial

Anthony G. Durmowicz, Robert Lim, Hobart Rogers et al. · Annals of the American Thoracic Society · 2017 · 139 citations

Molecular Pharmacology, Gene Therapies, Molecular Diagnostic Techniques +15

A Randomized, Controlled Trial of the Renal Effects of Ultrafiltration as Compared to Furosemide in Patients With Acute Decompensated Heart Failure

Hobart Rogers, Joanne Marshall, Jeremy S. Bock et al. · Journal of Cardiac Failure · 2008 · 109 citations

Hemodialysis, Heart Failure, Renal Effects +11

CYP2D6 Genotype Information to Guide Pimozide Treatment in Adult and Pediatric Patients

Hobart Rogers, Atul Bhattaram, Issam Zineh et al. · The Journal of Clinical Psychiatry · 2012 · 48 citations

Allopurinol Pharmacogenetics: Assessment of Potential Clinical Usefulness

Issam Zineh, Padmaja Mummaneni, Jenna Lyndly et al. · Pharmacogenomics · 2011 · 37 citations

Drug Safety, Allopurinol Use Data, Hla Variation +12

Association of genetic mutations and loss of ambulation in childhood‐onset dystrophinopathy

Gregory Haber, Kristin M. Conway, Pangaja Paramsothy et al. · Muscle & Nerve · 2020 · 20 citations · Full text